Format

Send to

Choose Destination
Leuk Lymphoma. 2016;57(6):1349-54. doi: 10.3109/10428194.2015.1096354. Epub 2015 Nov 16.

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.

Author information

1
a Inserm CIC1401 , Bordeaux , France ;
2
b Univ. Bordeaux , Bordeaux , France ;
3
c Inserm U657 , Bordeaux , France ;
4
d CHU Bordeaux , Bordeaux , France ;
5
e Polyclinique Bordeaux Nord , Bordeaux , France ;
6
f CHU Lille , Lille , France ;
7
g CHU Rouen , Rouen , France.

Abstract

Therapeutical options for older multiple myeloma patients have been improved with the advent of new drugs, yet there is a lack of observational data for such patients. To address this issue, an age-stratified analysis of the VESUVE cohort of bortezomib users was performed. Among the 779 patients included in the analysis, 358 (46%) were aged ≤ 65 years, 282 (36%) were between 65-75 years and 139 (18%) were more than 75 years old. There were few significant differences in treatment parameters across age groups; notably, older patients received a lower dose of bortezomib and more frequently experienced general or administration site conditions, metabolism or nutrition disorders and cardiac disorders. Overall best response rate and progression-free survival were similar across age groups. Taken together, these results indicate that older patients do benefit from bortezomib and that tailored treatment in real-life clinical practice does not compromise effectiveness.

KEYWORDS:

Bortezomib; aged; cohort studies; multiple myeloma; survival analysis

PMID:
26397802
DOI:
10.3109/10428194.2015.1096354
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center